Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Chief Financial Officer Appointment

On February 23, 2023, after the untimely passing of its Chief Financial Officer, the board of directors (the "Board") of Blonder Tongue Laboratories, Inc. (the "Company") appointed Michael Censoplano to Interim Chief Financial Officer of the Company, effective immediately (the "CFO Appointment").

Michael Censoplano, Interim CFO

Michael Censoplano, 50, has been with the Company for over 22 years, serving as the Company Controller since January 2001, and as the assistant controller from July 2000 through December 2000. Michael has an undergraduate degree from Rider University.





Family Relationships

Mr. Censoplano does not have a family relationship with any of the current officers or directors of the Company.





Related Party Transactions

There are no related party transactions with regard to Mr. Censoplano reportable under Item 404(a) of Regulation S-K.





Compensatory Arrangements

Mr. Censoplano shall receive an annual salary of $111,728.24 and as a full-time employee of the Company, will be eligible to participate in all of the Company's benefit programs.

Item 7.01 Regulation FD Disclosure

On February 23, 2023, the Company issued a press release announcing the CFO Appointment. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits



Exhibit No.   Description
99.1*           Press Release issued on February 23, 2023
104           Cover Page Interactive Data File (embedded within the Inline XBRL document).




 * Filed herewith.




                                       1

© Edgar Online, source Glimpses